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Abstract: Symptoms in Tourette syndrome (TS) are likely
related to abnormalities involving multiple neurotransmitter
systems in striatal-thalamo-cortical circuitry. Although prior
studies have found abnormal levels of tryptophan, serotonin,
and their metabolites in blood, cerebrospinal fluid and brain
tissue of TS patients, understanding of focal brain distur-
bances and their relationship to clinical phenotype remains
poor. We used -[11C]methyl-L-tryptophan (AMT) positron
emission tomography (PET) to assess global and focal brain
abnormalities of tryptophan metabolism and their relation-
ship to behavioral phenotype in 26 children with TS and nine
controls. Group comparisons on regional cortical and sub-
cortical AMT uptake revealed decreased AMT uptake in
bilateral dorsolateral prefrontal cortical and bilaterally in-
creased uptake in the thalamus (P  0.001) in TS children.
The ratio of AMT uptake in subcortical structures to dorso-
lateral prefrontal cortex was significantly increased bilater-
ally (P  0.01) in TS patients also. Behaviorally defined
subgroups within the TS sample revealed differences in the
pattern of AMT uptake in the fronto-striatal-thalamic circuit.
This study demonstrates cortical and subcortical abnormal-
ities of tryptophan metabolism in TS and provides neuroim-
aging evidence for a role of serotonergic mechanisms in the
pathophysiology of TS. © 2007 Movement Disorder Society
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Tourette syndrome (TS) is a neuropsychiatric disorder
characterized by motor and vocal tics, and is commonly
associated with neuropsychological deficits (e.g., visuo-
motor integration) and comorbid conditions such as ob-
sessive-compulsive disorder (OCD) and attention-deficit
hyperactivity disorder (ADHD).1 The pathophysiology
of TS is postulated to involve a dysfunction of cortico-
striatal-thalamic circuitry,2 which is supported by meta-
bolic imaging studies.3,4
Although previous imaging data favor an important
role of the dopaminergic system in TS symptomatology,5
in vivo studies indicate that serotonergic abnormalities
may also be important. Researchers have reported de-
creased blood levels of tryptophan in patients with TS
compared to controls,6,7 demonstrated that levels of tryp-
tophan in cerebrospinal fluid were inversely related to tic
severity in TS subjects,8 and found that levels of the
serotonin metabolite 5-HIAA in cerebrospinal fluid were
decreased in TS subjects following probenecid loading.9
In a study of postmortem brains from TS subjects,
Anderson et al.10 reported decreased levels of serotonin
and its metabolite 5-HIAA in a number of subcortical
regions. Altogether, these data strongly suggest that ab-
normal tryptophan metabolism may play a role in the
pathophysiology of TS.
In vivo studies of the serotonin system in TS have
included single photon emission computed tomography
(SPECT) studies to investigate serotonin transporter
*Correspondence to: Harry T. Chugani, Pediatric Neurology/PET
Center, Children’s Hospital of Michigan, 3901 Beaubien Blvd., De-
troit, MI 48201, USA. E-mail: hchugani@pet.wayne.edu
Received 6 March 2007; Revised 12 June 2007; Accepted 20 July
2007
Published online 20 August 2007 in Wiley InterScience (www.
interscience.wiley.com). DOI: 10.1002/mds.21712
Movement Disorders
Vol. 22, No. 15, 2007, pp. 2256–2262
© 2007 Movement Disorder Society
2256
binding (SERT) in TS, finding reduced SERT availabil-
ity in TS patients.11,12 Elevated 5-HT2A receptor binding
in adults with TS has also been found.13 These studies
support a relationship between TS and serotonergic neu-
rotransmission; however, the relationship of these find-
ings to tics and/or behavioral phenotype remains unclear.
Previously, there has been no direct method of imag-
ing and measuring cerebral serotonin metabolism in the
human brain. With the development of the new tracer
-[11C]methyl-L-tryptophan (AMT) and the use of
positron emission tomography (PET),14,15 it is now pos-
sible to image and measure tryptophan metabolism in TS
patients. Changes in global and regional AMT uptake
may closely reflect altered serotonin synthesis in the
brain, although increased AMT uptake may also occur
under specific conditions (such as inflammation) where
tryptophan metabolism is induced via the kynurenine
pathway.16
In this study, we sought to investigate whether TS
subjects manifest abnormal brain tryptophan metabolism
as compared to controls, and further, whether such ab-
normalities were associated with tics and behavioral phe-
notype. We hypothesized that TS subjects would show
abnormal regional tryptophan metabolism in fronto-stri-
atal-thalamic circuitry, and that the pattern of functional
abnormality would be associated with tic severity and
behavioral phenotype.
SUBJECTS AND METHODS
Twenty-six children (19 males, mean age  11.3
years; SD  3.0; age range: 5.7–18 years) with TS and
nine controls underwent AMT PET scans. All TS par-
ticipants were diagnosed by a pediatric neurologist. The
control group consisted of nine siblings of autistic chil-
dren (mean age: 10.1 years, age range: 8–15 years).17
None of the controls were taking medication prior to the
study, and none had current or historical diagnoses of
neurological or psychiatric disorder. Given that these
children were siblings of children with autism, presum-
ably an inherited disorder, all were assessed for the
presence of autistic symptoms as well as for behavioral
problems. None of the controls had significant elevations
on any of the subscales of the measures used.17 Age was
not significantly different between the groups (P 
0.27).
Nine of the 26 TS patients were taking medication for
TS or associated symptoms at the time of enrollment in
the study, while an additional 9 patients had taken med-
ication at some point prior to involvement in the study. In
order to control for medication effects on AMT PET
data, participants were placed into the following groups:
no medications (n  8), use of psychoactive medication
including SSRIs (n  7), and use of other psychoactive
medications (n  11).
All patients discontinued their medications 4 weeks
before their scheduled PET scan. Eleven patients were
given sedation because they could not remain still during
the PET scan; 10 oral diazepam, and 1 intravenous
nembutal followed by fentanyl. This study was con-
ducted with approval from Wayne State University Hu-
man Investigations Committee and written informed
consent was obtained from all participants prior to en-
rollment in the study.
Assessment of Tics, OCD and ADHD Comorbidity
Assessment of tics involved administration of the Tic
Symptom Self-Report (TSSR) measure.18 The TSSR is a
caregiver-report measure that assesses the type and se-
verity of motor and vocal tics over the past week. The
motor and vocal scores are composited into an overall tic
severity score, which was used as the index of tic sever-
ity for the present study. OCD symptoms were quantified
via semistructured interview (Children’s Yale-Brown
Obsessive Compulsive Scale).19 The operational defini-
tion for OCD in this study required a CYBOCS total
score of 15 (Ref. 20) and current diagnosis of OCD,
according to DSM-IV-TR criteria. ADHD comorbidity
was defined as current diagnosis of ADHD, as well as
clinically significant elevation on the Attention Problem
scale of the Behavioral Assessment Scale for Children
(BASC). The above measures have been demonstrated to
be psychometrically sound instruments.18,19,21
Four TS subgroups were identified: no comorbid di-
agnosis (“Pure” TS, n  11), OCD comorbid (OCD, n 
6), ADHD comorbid (ADHD, n  6), and a group
comorbid for both OCD and ADHD (n  3). Given the
small number of patients in the latter group, it was
dropped from further comparisons between subgroups.
Participants underwent comprehensive neuropsycholog-
ical evaluations. TS subgroups differed only on internal-
izing (OCD  Pure, ADHD; P  0.000) and external-
izing (ADHD  Pure, OCD; P  0.000) behavioral
problems. Subgroups did not differ on age or tic severity.
AMT PET Procedure.
PET studies were performed using the CTI/Siemens
EXACT/HR whole-body positron tomograph (Knox-
ville, TN) located in the Children’s Hospital of Michi-
gan, Detroit. The scanning protocol used in the present
study has been reported previously.22 In order to avoid
erroneous asymmetries due to image tilt, all image vol-
umes were resliced using a multipurpose 3D-registration
technique (MPItool).23
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Image Analysis.
Since all subjects received a standardized dose based
on their weight (0.1 mCi/kg), the averaged AMT images
(uCi/cm3) directly depict the standard uptake value
(SUV).15 Brain regions of interest (ROIs) were manually
defined on PET images, by a rater blind to diagnoses and
hypotheses, in both hemispheres for one cortical region
(DLPF) and three subcortical structures (thalamus, cau-
date, and lentiform nucleus). The average concentration
for each ROI was obtained as a weighted average over all
planes showing a particular region/structure. Addition-
ally, a whole brain ROI was defined including all supra-
tentorial planes and used to normalize regional SUVs to
whole brain SUV. This procedure resulted in normalized
SUVs for DLPF, thalamus, caudate, and lentiform nu-
cleus. In order to study the relationship between subcor-
tical and cortical AMT tracer uptake, we divided tracer
concentration in the thalamus, caudate, and lentiform
nucleus by concentration determined for the DLPF. This
resulted in a subcortical to cortical ratio (SCR) for the
thalamus, caudate and lentiform nucleus. Finally, an
asymmetry index (AI) was calculated for each region/
structure as follows: AI (%)  (L  R)/[(L  R)/2] 
100%, where L represents normalized SUVs in the left
hemisphere and R in the right hemisphere.
Statistical Analysis.
Initial analyses evaluated between-group differences
for medication use/type (one-way ANOVAs) and se-
dated versus nonsedated (independent samples t-test)
patients on AMT PET variables, to determine whether it
was necessary to control for medication use/type and/or
sedation in subsequent analyses.
Whole brain SUV was compared between the TS
group and controls using a univariate ANCOVA, con-
trolling for age. To investigate group differences be-
tween patients and controls on regional normalized
SUVs and SCRs, two separate 2 (group)  4 (region) 
2 (side) repeated measures ANCOVAs, controlling for
age, were performed. Simple effects tests were examined
following significant two or three way interaction(s). To
evaluate differences on normalized SUVs between TS
subgroups, a 3 (group)  4 (region)  2 (side) repeated
measures ANCOVA was applied controlling for tic se-
verity. Again, simple effects tests followed significant
interactions. To examine the association of tic severity to
regional normalized SUVs and AIs, we applied Pearson
correlations.
Given that the above mixed-model ANCOVAs design
includes some statistical control for multiple compari-
sons,24 we did not apply any correction to main effects or
interactions; interactions were examined further if sig-
nificant at P  0.05. However, the between-group com-
parison on whole brain SUV and correlations between tic
severity and normalized SUVs and AIs were adjusted
using Bonferroni correction for multiple comparisons in
order to reduce the likelihood of Type I error. Since there
were 13 tests the significance level for these analyses
was 0.004.
RESULTS
Whole Brain AMT Uptake, Effect of Medication
and Sedation
There were no differences between the medication
groups or sedation groups on whole brain AMT SUV,
normalized regional values, or cortical ratios. Therefore,
medication effect and use of sedation were not included
as covariates for comparisons on AMT PET variables.
The overall univariate ANCOVA for mean SUV for
the whole brain was not significant although there was a
trend for reduced uptake in TS (P  0.02).
Differences in Regional AMT Uptake and
Subcortical-Cortical Ratios Between TS Patients
and Controls
The group  region interaction for regional AMT
SUV was significant (P  0.000). Simple effects tests
showed that TS patients had significantly reduced nor-
malized SUVs in the bilateral DLPF (left P  0.001;
right P  0.001) and increased normalized SUVs in the
bilateral thalamus (left P  0.001; right P  0.000) (Fig.
1). For SCRs, the group  region interaction (P  0.00)
was significant. Simple effects tests showed higher SCRs
in the bilateral thalamus (left P  0.000; right P 
0.000), bilateral caudate (left P  0.000; right P 
0.002) and bilateral lentiform nucleus (left P  0.002;
right P  0.008) (Fig. 2) in TS patients.
FIG. 1. Normalized AMT SUVs for DLPF, thalamus, caudate and
basal ganglia by group. AMT SUVs were lower bilaterally in DLPF
and higher in bilateral thalamus in patients versus controls. Significance
is indicated by an asterisk.
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Differences in Regional AMT Uptake Between
Behaviorally Defined TS Subgroups
The overall TS (sub)group  region  side interaction
for normalized regional values was significant (P 
0.046). Follow-up tests revealed decreased right DLPF
for the ADHD group compared to the OCD and Pure TS
groups (P  0.002), and opposite subcortical patterns for
the ADHD (left  right basal ganglia (caudate, lenti-
form); right  left thalamus) and OCD (right  left basal
ganglia; left  right thalamus) groups (see Figs. 3 and 4).
Relationship of AMT Uptake with Tic Severity
Correlations within the TS group between tic severity
and regional normalized values and AIs for the four
regions tested were not significant, although there was a
trend for increased tic severity and increased right  left
thalamic asymmetry (P  0.021).
DISCUSSION
This study demonstrates cortical and subcortical ab-
normalities of in vivo tryptophan metabolism in TS pa-
tients. Some of the regional abnormalities of AMT up-
take appear to be related to TS per se, others with
behavioral phenotype. Although abnormal AMT uptake
may occur both due to altered serotonin synthesis and
increased tryptophan metabolism via the kynurenine
pathway, the latter requires an inflammatory condition or
presence of a tumor, which is not the case in TS. Thus,
findings provide novel neuroimaging evidence demon-
strating the role of abnormal serotonergic metabolism in
the pathophysiology of TS, and add to the body of work
suggesting abnormal serotonergic transmission in
TS.11–13
Neuroimaging Findings in TS
Previous neuroimaging studies have suggested abnor-
malities in the subcortical components of the fronto-
striato-thalamic circuit in TS. For example, a recent PET
FIG. 2. Subcortical–cortical ratios (SCR) for the caudate, basal gan-
glia, and thalamus by group. SCR of 1 represents SUV equal to the
DLPF. SCRs in all structures were significantly increased bilaterally in
the TS group. Significance is indicated by an asterisk.
FIG. 3. Normalized SUV for the left and right ROIs for controls and
TS subgroups. The ADHD subgroup shows significantly reduced up-
take in right DLPF and opposite asymmetries (leftright) in basal
ganglia and thalamus; the OCD subgroup shows an opposite pattern.
FIG. 4. Distribution of AMT uptake for 13-year-old male with TS and
comorbid ADHD. (A) shows leftright uptake in the caudate nucleus
(and basal ganglia more generally), and (B) shows the rightleft in the
thalamus.
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study revealed reduced 5-HT2A receptor binding in the
basal ganglia (and other brain regions).13 MRI volumet-
ric studies of subcortical nuclei in TS reported decreased
basal ganglia and thalamic volumes, including volume
decreases in the caudate nucleus.25 Interestingly, our
present study showed increased AMT uptake in caudate
nuclei and thalamus for the TS group (Fig. 1). Since
decreased caudate volume by itself would likely cause a
decrease in apparent AMT uptake, such increases on
PET are unlikely to be explained by volume loss, which
would lead to decreased apparent uptake without correc-
tion for volume differences. Indeed, in structures with a
presumed moderate volume loss (such as the caudate
nucleus), our measured values may have slightly under-
estimated AMT uptake. Previous PET studies evaluating
involvement of the dopaminergic system in TS have
reported elevated striatal dopamine transporter levels,6
abnormal presynaptic DOPA decarboxylase activity,26
and increased dopamine release in the striatum of pa-
tients with TS.27 Our findings provide the first imaging
evidence of abnormal tryptophan metabolism in the
fronto-striato-thalamic circuit in TS.
In addition to subcortical abnormalities, there is also
imaging support for involvement of the frontal lobe in
the pathology of TS. Recent MRI studies have shown
decreased deep white matter volumes of the frontal cor-
tex, smaller right frontal lobe,28 and variable volume
changes in frontal regions in TS patients.29 A dispropor-
tionate increase of frontal lobe white matter has also
been described.30 FDG PET studies have reported both
decreased and increased normalized glucose metabolic
rates in various parts of the frontal lobe.31–33 In the
present study, we found DLPF cortical decreases of
AMT uptake in TS patients as compared to controls, and
further, increased ratios of AMT uptake in subcortical
structures to DLPF AMT uptake (Fig. 2). These findings
suggest a general impairment of cortical-subcortical se-
rotonergic function in TS.
Correlations with Neuropsychological Findings
Results of the present study suggest that cortical-
subcortical dysregulation is associated with TS per se
(Figs. 1 and 2), whereas phenotypic presentation may be
associated with the pattern of relationships in AMT up-
take among components of the fronto-striato-thalamic
circuit (Figs. 3 and 4). Specifically, OCD and ADHD
comorbid subgroups were associated with different pat-
terns of AMT uptake; patterns that are consistent with
previous neuroscience research on these diagnostic prob-
lems.34–38 These results provide support for the potential
usefulness of creating more homogeneous groups within
the TS population in research evaluating brain–behavior
relationships.
Implications in Pathophysiology of TS
One of the current theories on pathomechanisms of TS
suggests an imbalance between direct and indirect
striato-pallidal pathway tone, causing overactivity in
neuronal circuits controlled by various neurotransmitter
systems.39 This imbalance may be responsible for hy-
perkinetic movements and behavioral dysfunction. Our
present data suggest a cortico-subcortical imbalance in
the serotonergic system. Serotonergic neurons are known
to have inhibitory influence on dopamine metabolism
and on the function of dopamine neurons; destruction of
the raphe nuclei in animal experiments results in elevated
dopamine activity in the striatum.40 However, because of
the close pathogenetic, metabolic, and genetic correla-
tions among various neurotransmitter systems, determin-
ing which dysfunction is primary, secondary, or inciden-
tal, remains a challenge. Of note is that, unlike TS, most
movement disorders that are primarily associated with
dopamine dysfunction have a progressive course.
Increased subcortical, including striatal, AMT uptake
in TS patients may indicate an overproduction of exci-
tatory tryptophan metabolites. Indeed, chronic striatal
infusion of quinolinic acid in rats results in motor ste-
reotypies.41 The resulting excitotoxic brain injury may
also account for the volume loss in the caudate nucleus
found in patients with TS. It is also possible that the
actual tracer uptake shown by AMT PET depends on
which stage of the disease is studied. Future studies
comparing striatal AMT uptake during exacerbation of
motor tics versus periods with relatively mild symptoms
in the same individual could test this hypothesis.
Implication of increased quinolinic acid production in
the striatum may also link abnormal tryptophan metab-
olism to the well-documented abnormalities of dopamine
metabolism in TS. Activation of NMDA receptors by
increased quinolinic acid production may lead to in-
creased striatal dopamine release; this has been reported
following activation of NMDA receptors.42 In addition, it
has been shown that quinolinic acid injections in rat
striatum can cause degeneration of GABAergic neu-
rons,43 which are essential components of frontal-sub-
cortical circuits.39 These inhibitory neurons, which are
located in both cortical and basal ganglia regions, pro-
vide the primary projections for both the globus pallidus
interna (direct) and globus pallidus externa (indirect)
pathways. GABA-modulating agents have been used
with moderate success in the treatment of tics.44
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Methodological Issues
Some methodological issues should be considered
when interpreting our findings. Theoretically, sympatho-
mimetic therapy may interfere with cerebral serotonin
metabolism. While all patients stopped their medications
4 weeks before AMT PET scanning and while compar-
isons between medication groups showed no differences
in global or regional AMT uptake, it remains possible
that medication effects persisted. Another methodologi-
cal issue is that no MRI-based correction for partial
volume effects was performed in our patients. Thus, it
cannot be entirely excluded that some of the findings
were confounded by subtle structural changes (e.g., vol-
ume loss). However, major findings included increases
in AMT uptake in subcortical structures, several of
which are reported to be structurally smaller in TS.25
These findings are unlikely to be due to partial volume
effects. Nevertheless, future PET studies in TS should
directly compare quantitative MRI data with PET find-
ings. Finally, while categorization of patients according
to their neuropsychological profile resulted in phenotyp-
ically more homogeneous groups and revealed further
regional abnormalities, given the small sample size of the
diagnostic groups, the findings are considered prelimi-
nary and warrant further AMT PET studies of TS pa-
tients with and without comorbid conditions.
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